Recent progress in broadly neutralizing antibodies to HIV (Q58569712)

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Passive immunotherapy of viral infections: 'super-antibodies' enter the fray

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Progress toward active or passive HIV-1 vaccination

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure.

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Identification and specificity of broadly neutralizing antibodies against HIV

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Use of broadly neutralizing antibodies for HIV-1 prevention

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Prospects for passive immunity to prevent HIV infection

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy?

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design.

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

A Broadly Neutralizing Antibody Targets the Dynamic HIV Envelope Trimer Apex via a Long, Rigidified, and Anionic β-Hairpin Structure

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

A Prominent Site of Antibody Vulnerability on HIV Envelope Incorporates a Motif Associated with CCR5 Binding and Its Camouflaging Glycans.

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Structure and immune recognition of trimeric pre-fusion HIV-1 Env.

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Immunologic Insights on the Membrane Proximal External Region: A Major Human Immunodeficiency Virus Type-1 Vaccine Target.

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

A Neutralizing Antibody Recognizing Primarily N-Linked Glycan Targets the Silent Face of the HIV Envelope.

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Crystal Structure of PG16 and Chimeric Dissection with Somatically Related PG9: Structure-Function Analysis of Two Quaternary-Specific Antibodies That Effectively Neutralize HIV-1

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Glycans Function as Anchors for Antibodies and Help Drive HIV Broadly Neutralizing Antibody Development

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

HIV Envelope Glycoform Heterogeneity and Localized Diversity Govern the Initiation and Maturation of a V2 Apex Broadly Neutralizing Antibody Lineage

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Co-evolution of HIV Envelope and Apex-Targeting Neutralizing Antibody Lineage Provides Benchmarks for Vaccine Design.

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Early Antibody Lineage Diversification and Independent Limb Maturation Lead to Broad HIV-1 Neutralization Targeting the Env High-Mannose Patch

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Multiple Antibody Lineages in One Donor Target the Glycan-V3 Supersite of the HIV-1 Envelope Glycoprotein and Display a Preference for Quaternary Binding

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

HIV-1 Neutralizing Antibodies with Limited Hypermutation from an Infant

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Structural characterization of a highly-potent V3-glycan broadly neutralizing antibody bound to natively-glycosylated HIV-1 envelope.

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth.

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Identification of Near-Pan-neutralizing Antibodies against HIV-1 by Deconvolution of Plasma Humoral Responses

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen.

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

The human naive B cell repertoire contains distinct subclasses for a germline-targeting HIV-1 vaccine immunogen

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Rapid elicitation of broadly neutralizing antibodies to HIV by immunization in cows

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Human peripheral blood antibodies with long HCDR3s are established primarily at original recombination using a limited subset of germline genes

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Complete functional mapping of infection- and vaccine-elicited antibodies against the fusion peptide of HIV

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Lipid interactions and angle of approach to the HIV-1 viral membrane of broadly neutralizing antibody 10E8: Insights for vaccine and therapeutic design.

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Potent and broad HIV-neutralizing antibodies in memory B cells and plasma

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Site-Specific Glycosylation of Virion-Derived HIV-1 Env Is Mimicked by a Soluble Trimeric Immunogen

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Unprecedented Role of Hybrid N-Glycans as Ligands for HIV-1 Broadly Neutralizing Antibodies.

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection.

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

In vivo protection by broadly neutralizing HIV antibodies

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Animal models in HIV-1 protection and therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Generation and evaluation of clade C simian-human immunodeficiency virus challenge stocks

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail.

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

High-multiplicity HIV-1 infection and neutralizing antibody evasion mediated by the macrophage-T cell virological synapse.

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Cell-to-cell spread of HIV-1 and evasion of neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Capacity of Broadly Neutralizing Antibodies to Inhibit HIV-1 Cell-Cell Transmission Is Strain- and Epitope-Dependent

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Broadly neutralizing antibodies that inhibit HIV-1 cell to cell transmission

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Neutralisation of HIV-1 cell-cell spread by human and llama antibodies.

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Partial efficacy of a broadly neutralizing antibody against cell-associated SHIV infection

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Neutralizing antibody affords comparable protection against vaginal and rectal simian/human immunodeficiency virus challenge in macaques.

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Humoral and Cell-Mediated Immune Responses to Alternate Booster Schedules of Anthrax Vaccine Adsorbed in Humans

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Antibody 10-1074 suppresses viremia in HIV-1-infected individuals

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Anti-retroviral antibody FcγR-mediated effector functions

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

CATNAP: a tool to compile, analyze and tally neutralizing antibody panels

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1.

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Generation of Human Monoclonal Antibodies against HIV-1 Proteins; Electrofusion and Epstein-Barr Virus Transformation for Peripheral Blood Lymphocyte Immortalization

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Broad neutralization coverage of HIV by multiple highly potent antibodies

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Broad and potent neutralization of HIV-1 by a gp41-specific human antibody

1 reference

https://api.crossref.org/works/10.1038%2FS41590-018-0235-7

7 January 2021

Dose-response curve slope helps predict therapeutic potency and breadth of HIV broadly neutralizing antibodies

1 reference

12 December 2020

Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs

1 reference

12 December 2020

Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide.

1 reference

12 December 2020

Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials

1 reference

12 December 2020

Differential processing of HIV envelope glycans on the virus and soluble recombinant trimer

1 reference

12 December 2020